As AI proliferates, biopharma companies seek to harness it in clinical trials; Genmab to buy ProfoundBio for $1.8 billion

Taking stock of the drug industry, from the lab to the medicine chest

April 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | As AI proliferates, biopharma companies seek to harness it in clinical trials The concept is particularly appealing in oncology, where new medications that focus on smaller subsets of patients can make it difficult to enroll trials. By Allison DeAngelis STAT+ | Genmab to buy ProfoundBio for $1.8 billion, the latest deal focused on targeted chemotherapies The $1.8 billion deal is the latest acquisition centered on antibody-drug conjugates, which deliver chemotherapies directly to tumor sites. By Andrew Joseph STAT+ | Investors funnel $275 million into Paragon Therapeutics spinout The new Oruka Therapeutics launched Wednesday through a reverse merger with ARCA biopharma, a Colorado biotech. By Allison DeAngelis Adobe Opinion: Medicare coverage of weight loss drugs could save the U.S. billions of dollars The newest weight loss drugs are expensive. But their broader use could save the U.S. billions of dollars in health care costs. By Dana P. Goldman and Alison Sexton Ward STAT+ | The White House has a plan to stem drug shortages Improving manufacturing resilience and hospital purchasing practices are part of the plan to stem persistent drug shortages, including cancer therapies. By John Wilkerson

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser